IL138919A0 - Use of nmda antagonists for treatment of irritable bowel syndrome - Google Patents

Use of nmda antagonists for treatment of irritable bowel syndrome

Info

Publication number
IL138919A0
IL138919A0 IL13891999A IL13891999A IL138919A0 IL 138919 A0 IL138919 A0 IL 138919A0 IL 13891999 A IL13891999 A IL 13891999A IL 13891999 A IL13891999 A IL 13891999A IL 138919 A0 IL138919 A0 IL 138919A0
Authority
IL
Israel
Prior art keywords
treatment
bowel syndrome
irritable bowel
nmda antagonists
nmda
Prior art date
Application number
IL13891999A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801494A external-priority patent/SE9801494D0/xx
Priority claimed from SE9803954A external-priority patent/SE9803954D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL138919A0 publication Critical patent/IL138919A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13891999A 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome IL138919A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
SE9803954A SE9803954D0 (sv) 1998-11-18 1998-11-18 Novel use
PCT/SE1999/000702 WO1999055323A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
IL138919A0 true IL138919A0 (en) 2001-11-25

Family

ID=26663287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13891999A IL138919A0 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome

Country Status (21)

Country Link
EP (1) EP1073431B1 (ko)
JP (1) JP2002512956A (ko)
KR (1) KR100569777B1 (ko)
CN (1) CN1200702C (ko)
AR (1) AR016212A1 (ko)
AT (1) ATE270545T1 (ko)
AU (1) AU760783B2 (ko)
BR (1) BR9909971A (ko)
CA (1) CA2329328A1 (ko)
DE (1) DE69918541T2 (ko)
DK (1) DK1073431T3 (ko)
ES (1) ES2221753T3 (ko)
HK (1) HK1033876A1 (ko)
IL (1) IL138919A0 (ko)
MY (1) MY121063A (ko)
NO (1) NO20005386D0 (ko)
NZ (1) NZ507436A (ko)
PT (1) PT1073431E (ko)
SA (1) SA99200482B1 (ko)
TW (1) TW570793B (ko)
WO (1) WO1999055323A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5042425B2 (ja) * 2000-03-01 2012-10-03 ユーロセルティック ソシエテ アノニム 機能性胃腸疾患治療用トラマドール
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
WO2020006629A1 (en) * 2018-07-06 2020-01-09 Algernon Pharmaceuticals Inc. Compounds for treatment of inflammatory bowel disease and methods thereof
KR102211282B1 (ko) 2019-11-20 2021-02-03 (주)파이브텍 데이터 라우팅 방법 및 이를 지원하는 스위치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
AU4302499A (en) 1999-11-16
NO20005386L (no) 2000-10-26
ES2221753T3 (es) 2005-01-01
DE69918541T2 (de) 2005-08-18
ATE270545T1 (de) 2004-07-15
WO1999055323A1 (en) 1999-11-04
JP2002512956A (ja) 2002-05-08
CN1307471A (zh) 2001-08-08
HK1033876A1 (en) 2001-09-28
BR9909971A (pt) 2000-12-26
CN1200702C (zh) 2005-05-11
NZ507436A (en) 2003-09-26
CA2329328A1 (en) 1999-11-04
AR016212A1 (es) 2001-06-20
TW570793B (en) 2004-01-11
PT1073431E (pt) 2004-10-29
NO20005386D0 (no) 2000-10-26
KR100569777B1 (ko) 2006-04-11
EP1073431B1 (en) 2004-07-07
AU760783B2 (en) 2003-05-22
DE69918541D1 (de) 2004-08-12
KR20010043077A (ko) 2001-05-25
EP1073431A1 (en) 2001-02-07
MY121063A (en) 2005-12-30
SA99200482B1 (ar) 2006-06-27
DK1073431T3 (da) 2004-10-04

Similar Documents

Publication Publication Date Title
HU0003386D0 (en) Use of crf antagonists
ZA200107291B (en) Use of xenon for treating neurointoxications.
ZA989150B (en) Mouth hygienic composition for the treatment of halitosis
HUP9800938A3 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
GB2335623B (en) Cleaning apparatus
PL330195A1 (en) Antagonist of dopamine d4 receptor
GB2361630B (en) Cleaning apparatus
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
GB9909185D0 (en) Cleaning apparatus
HU9702039D0 (en) Estrogen agonist/antagonists treatment of atheroscerosis
IL138919A0 (en) Use of nmda antagonists for treatment of irritable bowel syndrome
PL333079A1 (en) Piparazinic derivatives as antagonists of neurokinin
GB9923374D0 (en) Cleaning apparatus
SI1607090T1 (sl) Asimadolin za zdravljenje sindroma razdraĹľljivega ÄŤrevesa
SI1073431T1 (en) Use of nmda antagonists for treatment of irritable bowel syndrome
ZA981206B (en) Use of NMDA receptor antagonist
GB9928314D0 (en) Composition for the treatment of irritable bowel syndrome
IL130425A0 (en) Process for the preparation of NMDA antagonists
SI1104289T1 (sl) Novi oralni pripravki 5-HT4 agonistov ali antagonistov
EG21680A (en) Process for the preparation of ampicillin
GB9815500D0 (en) Hand cleansing apparatus
GB9603243D0 (en) Process for the preparation of an endothelin antagonist
GB9811174D0 (en) Elbow rest
PL318534A1 (en) (azetydin-1-nylalkyl)lactams as antagonists of tachykinins
SI1133290T1 (en) Use of inhibitors of acetylcholinesterase for the treatment of deliriums

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees